Resistance in the land of molecular cancer therapeutics

Slides:

Advertisements

Similar presentations

Imatinib Resistance Geoffrey L. Uy, M.D. Associate Professor of Medicine Division of Oncology.

Advertisements

The National CML Society 2012 CML UPDATE “What’s New? What’s Coming?” Luke Akard MD Co-Director Indiana Blood and Marrow Transplantation Program.

A Role for Dystroglycan in Basement Membrane Assembly Michael D Henry, Kevin P Campbell Cell Volume 95, Issue 6, Pages (December 1998) DOI: /S (00)

Lessons from Hereditary Colorectal Cancer

Smaug, a Novel RNA-Binding Protein that Operates a Translational Switch in Drosophila Anupama Dahanukar, James A Walker, Robin P Wharton Molecular Cell.

Cancer Metabolism Cell Volume 148, Issue 3, (February 2012) DOI: /j.cell Copyright © 2012 Terms and Conditions Terms and Conditions.

Questions to the Committee. Question 1. The Agency has accepted durable responses in hematologic malignancies for approval for both chronic leukemias.

Treatment of CML. Goal of Therapy Complete molecular remission and cure – Achieve prolonged, durable, nonneoplastic, nonclonal hematopoiesis, – Eradication.

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell Volume.

Chronic myelogenous leukemia Uncommon disease Highly lethal when ineffectively Rxd Most pts are in their 50s+60s The molecular understanding of this disease.

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis.

A Two-Step Scaffolding Model for Mitotic Chromosome Assembly Kazuhiro Maeshima, Ulrich K. Laemmli Developmental Cell Volume 4, Issue 4, Pages (April.

Genetic testing for high-risk colon cancer patients1 William M. Grady Gastroenterology Volume 124, Issue 6, Pages (May 2003) DOI: /S (03)

Case report Sudden blastic transformation in patient with chronic myeloid leukemia treated with imatinib mesylate Mehrdad Payandeh,MD Hematology, Medical.

Figure Molecular Biology of the Cell (© Garland Science 2008)

Kamyar Kalantar-Zadeh Kidney International

Shah N et al. Proc ASH 2010;Abstract 206.

Epidemiology and Treatment of Lung Cancer in Seattle

Volume 1, Issue 5, Pages (November 2007)

Cortes JE et al. Proc ASCO 2010;Abstract 6502.

Monitoring and Prevention of Relapse after Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies Ulrike Bacher, Julie-An Talano, Michael.

How to Treat MDS without Stem Cell Transplantation

Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams

Luis A. Carvajal, Ulrich Steidl Cell Stem Cell

Accelerating drug discovery: Open source cancer cell biology?

Cliques and Schisms of Cancer Genes

Volume 2, Issue 3, Pages (September 2002)

MDS Is a Stem Cell Disorder After All

David J. Brenner, Eric J. Hall, Rochelle E. Curtis, Elaine Ron

The AML Salad Bowl Cancer Cell

It's ALL in the diagnosis

New Views into the Genetic Landscape of Metastatic Breast Cancer

In This Issue Cell Volume 158, Issue 5, (August 2014)

It's ALL in the diagnosis

Quiz Page July 2009 American Journal of Kidney Diseases

Jacob M. Rowe Biology of Blood and Marrow Transplantation

Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without.

Volume 2, Issue 2, Pages (August 2002)

Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia Vivian.

Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions Darius Sairafi, Mats Remberger, Michael.

Targeting β-catenin in CML: Leukemia Stem Cells Beware!

Volume 14, Issue 6, Pages (December 2008)

Kamyar Kalantar-Zadeh Kidney International

Theodoros Karantanos, Timothy C. Thompson Cancer Cell

PPARγ: Welcoming the New Kid on the CML Stem Cell Block

Patients with Philadelphia-Positive Leukemia with BCR-ABL Kinase Mutations before Allogeneic Transplantation Predominantly Relapse with the Same Mutation

Daynna J. Wolff, Adam Bagg, Linda D. Cooley, Gordon W. Dewald, Betsy A

Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy.

Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies Robert.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy Naomi E. Verstegen,

On the Design of Combination Cancer Therapy

847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach Molecular.

660. Bowel/Bladder Sensation and Control in Patients with Spinal Cord Injury Treated with Human Embryonic Stem Cell Therapy Geeta Shroff Molecular Therapy

Volume 21, Issue 8, Pages (August 2013)

Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice Abdalla Awidi, Salah Abbasi,

Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom Haesook T. Kim, Philippe Armand Biology of Blood.

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Elias Jabbour, MD, Jorge E. Cortes,

Mammen Chandy Biology of Blood and Marrow Transplantation

Mutations and aneuploidy

Treatment versus Transplant for Challenging Hematologic Disorders

Volume 82, Issue 9, Pages (November 2012)

Chronic Myeloid Leukemia: MD-2025 Chisinau, Republic of Moldova

Guru Sonpavde, MD, Teresa G. Hayes, MD Mayo Clinic Proceedings

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Attacking Cancer at Its Root

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Ibrutinib Treatment of CLL: The Cancer Fights Back

The AML Salad Bowl Cancer Cell

Presentation transcript:

Resistance in the land of molecular cancer therapeutics Kevin M Shannon Cancer Cell Volume 2, Issue 2, Pages 99-102 (August 2002) DOI: 10.1016/S1535-6108(02)00101-0

Figure 1 Patterns of imatinib resistance in CML Patients treated with imatinib either clear the Philadelphia chromosome from the bone marrow (complete cytogenetic response) or demonstrate primary molecular resistance to the drug. Many patients with molecular resistance have a sustained hematologic response and benefit from continuing treatment. Among patients with cytogenetic responses, some will acquire resistance to imatinib and will relapse with reemergence of the Philadelphia chromosome in the bone marrow. Cancer Cell 2002 2, 99-102DOI: (10.1016/S1535-6108(02)00101-0)